Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CYCLAFEM 7/7/7 vs AFIRMELLE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination estrogen-progestin contraceptive. Ethinyl estradiol suppresses gonadotropin release (FSH, LH) via negative feedback on hypothalamic-pituitary axis; norethindrone induces endometrial changes that inhibit implantation and thickens cervical mucus.
Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.
Prevention of pregnancy (FDA-labeled),Treatment of moderate acne vulgaris in women ≥15 years (FDA-labeled for some triphasic formulations),Off-label: dysmenorrhea, endometriosis-associated pain, menstrual irregularity
Prevention of pregnancy (FDA-approved)
One tablet (norethindrone 0.5 mg/ethinyl estradiol 35 mcg) orally once daily for 7 days, then one tablet (norethindrone 0.75 mg/ethinyl estradiol 35 mcg) orally once daily for 7 days, then one tablet (norethindrone 1 mg/ethinyl estradiol 35 mcg) orally once daily for 7 days. Dispensed in a 21-tablet pack with 7 placebo tablets. For contraception, take one tablet daily at same time each day for 28 days; begin next pack after 28-day cycle.
One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.
Terminal half-life: 5-13 hours (mean 8 hrs); clinical context: supports every-28-day dosing interval for intramuscular depot.
Terminal elimination half-life: 12–15 hours. Steady-state achieved within 5 days with Q12H dosing.
Primarily hepatic via CYP3A4 hydroxylation and conjugation; ethinyl estradiol undergoes first-pass metabolism and enterohepatic recirculation. Norethindrone is metabolized to various reduced and conjugated metabolites.
Ethinyl estradiol undergoes first-pass metabolism in gut and liver via CYP3A4, with conjugation to sulfate and glucuronide. Levonorgestrel is metabolized primarily by CYP3A4 to reduced and hydroxylated metabolites, then conjugated.
Renal: ~50-60% as conjugated metabolites; Fecal: ~30-40% via bile; <1% unchanged.
Renal: 50% as unchanged drug and metabolites; fecal: 40% as metabolites; biliary: ~10% as glucuronide conjugates.
~97-99% bound, primarily to sex hormone-binding globulin (SHBG) and albumin.
~99% bound to serum albumin and sex hormone-binding globulin.
2.5-4.5 L/kg; extensive tissue distribution including adipose tissue, brain, and reproductive organs.
2.8 L/kg (apparent Vd), indicating extensive tissue distribution.
Oral: ~100% (combination with ethinyl estradiol enhances absorption); IM: 100% (depot formulation).
Oral: ~70% due to first-pass metabolism.
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (GFR <30 m L/min); use is not recommended due to potential hormonal accumulation and increased thrombotic risk.
No dose adjustment required for mild to moderate renal impairment. Not recommended for use in end-stage renal disease.
Contraindicated in acute or chronic hepatic dysfunction (Child-Pugh class B or C) due to impaired metabolism of estrogen and progestin. For mild hepatic impairment (Child-Pugh class A), limited data; use alternative contraception if possible.
Contraindicated in acute hepatic disease or severe (Child-Pugh C) hepatic impairment. Use with caution in mild to moderate hepatic impairment; monitor liver function.
Safety and efficacy not established in females younger than 18 years for contraception; however, postmenarchal adolescents may use standard adult dosing (after menarche). Weight-based dosing not applicable; use weight ≥45 kg with no dose adjustment. For other indications (e.g., acne), follow adult dosing in patients ≥15 years.
Not indicated for use before menarche. Post-menarche: same as adult dosing (one tablet daily) based on adult clinical trials.
Not indicated for postmenopausal women (age >55 years) as no contraceptive benefit. If used off-label, no specific dose adjustment; however, consider increased risk of cardiovascular events (thrombosis, hypertension, stroke) and metabolic effects (glucose intolerance, lipid changes) in older women with additional risk factors. Use lowest effective dose if necessary.
Not indicated for use in postmenopausal women; no specific dose adjustment required in healthy elderly, but limited data available.
Cigarette smoking increases risk of serious cardiovascular events (myocardial infarction, thromboembolism, stroke) from combination oral contraceptive use, especially in women >35 years and those who smoke ≥15 cigarettes/day.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age (especially in women over 35) and with heavy smoking (15+ cigarettes/day). Women who use combination hormonal contraceptives should be strongly advised not to smoke.
Thromboembolic disorders (DVT, PE, stroke, MI) – discontinue if symptoms occur,Hepatic disease (jaundice, hepatitis, cholestasis) – discontinue if develops,Hypertension – monitor blood pressure; discontinue if uncontrolled,Gallbladder disease – increased risk of cholelithiasis,Carbohydrate/lipid metabolism – monitor in diabetic or hyperlipidemic patients,Headache (including migraine) – discontinue if new or worsening,Uterine bleeding – rule out pregnancy if amenorrhea occurs,Depression – discontinue if severe,Ocular lesions (retinal thrombosis) – discontinue if visual disturbances occur
Thrombotic disorders (venous thromboembolism, stroke, myocardial infarction),Cigarette smoking (increases cardiovascular risk),Hypertension (especially in women with renal disease or migraines),Gallbladder disease,Hepatic neoplasia (benign and malignant),Carbohydrate and lipid metabolism effects,Ocular lesions (retinal thrombosis),Depressed mood or depression,Uterine bleeding irregularities,Reduced efficacy with hepatic enzyme inducers
Smoking >15 cigarettes/day and age ≥35 years,History of DVT/PE or thromboembolic disorders,Cerebrovascular or coronary artery disease,Uncontrolled hypertension,Diabetes with vascular involvement,Migraine with focal aura (especially if >35 years),Breast cancer (current or history),Estrogen-dependent neoplasia,Liver tumors (benign or malignant) or active liver disease,Pregnancy or suspected pregnancy,Undiagnosed abnormal uterine bleeding,Use of ritonavir-boosted protease inhibitors (CYP3A4 induction reduces efficacy)
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast cancer, endometrial cancer, or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Hepatic adenoma or carcinoma (current or history),Known or suspected pregnancy,Hypersensitivity to any component of the product,Heavy smoking (≥15 cigarettes/day) in women over 35
No specific dietary restrictions are required. Grapefruit and grapefruit juice may modestly increase ethinyl estradiol levels, but this is not considered clinically relevant in most cases. Avoid excessive grapefruit intake to be cautious. The medication can be taken with or without food. High-fat meals may delay absorption of the hormones, but overall contraceptive efficacy is not affected.
Grapefruit juice may increase ethinyl estradiol levels; avoid large quantities. No significant food restrictions. Administer with food if GI upset occurs.
Pregnancy Category X. First trimester: Major birth defects including neural tube defects, cardiovascular malformations, and oral clefts. Second/third trimester: Fetal demasculinization in males, potential for feminization. Post-natal: Long-term reproductive tract abnormalities.
Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defects). Second and third trimesters: increased risk of fetal growth restriction, preterm birth, and neonatal respiratory distress. Postnatal: possible long-term developmental effects.
Excreted in breast milk. M/P ratio ~0.2. Avoid breastfeeding due to potential estrogenic effects on infant. Alternative methods recommended.
Contraindicated during breastfeeding. Small amounts of ethinyl estradiol and norethindrone are excreted in breast milk; M/P ratio not well defined. Potential for adverse effects on infant (e.g., jaundice, breast enlargement). May reduce milk production and quality.
Contraindicated in pregnancy. No dose adjustments applicable. Discontinue immediately if pregnancy occurs.
Contraindicated in pregnancy; no dose adjustment recommended. If exposure occurs, immediate discontinuation is required. No pharmacokinetic data support safe use; avoid use entirely.
Cyclafem 7/7/7 is a triphasic combined oral contraceptive containing ethinyl estradiol and norethindrone. The varying hormone doses across the three 7-day phases mimic the natural menstrual cycle. It is essential to start the first pack on the first day of menses for immediate contraceptive efficacy. Missed pills require specific instructions based on the week; if one pill is missed, take it as soon as remembered and continue. If two pills are missed in week 1 or 2, take two pills for two days, then resume. If two pills are missed in week 3, or three or more pills are missed at any time, use backup contraception for 7 days and consider starting a new pack. Breakthrough bleeding is common, especially in the first few cycles, and does not indicate contraceptive failure. Grapefruit juice may increase ethinyl estradiol levels, but clinical significance is minimal; still, avoid excessive intake.
Afirmelle (levonorgestrel/ethinyl estradiol) is a combined oral contraceptive. Counsel patients to take at the same time daily to maintain consistent hormone levels. Use back-up contraception if a dose is missed. Monitor for signs of thromboembolism, especially in smokers over 35. Advise that certain antibiotics (e.g., rifampin) and anticonvulsants (e.g., phenytoin) may reduce efficacy. Consider progestin-only pill if contraindications to estrogen exist.
Take one pill daily at the same time each day, following the order of the pills in the pack (7 light yellow, 7 orange, 7 light green, then 7 white placebo).,If you miss a pill, refer to the package insert instructions based on how many pills you missed and the week you are in; use backup contraception if needed.,Common side effects include nausea, breast tenderness, and breakthrough bleeding, especially in the first 3 cycles; report severe symptoms.,Smoking increases the risk of serious cardiovascular side effects, especially in women over 35; do not smoke while on this medication.,Not all women can use combination oral contraceptives; inform your doctor if you have a history of blood clots, migraines with aura, liver disease, or certain cancers.,Use backup contraception (e.g., condoms) for the first 7 days if starting for the first time or after a break of more than 7 days.,Missed pills, vomiting, or diarrhea may reduce effectiveness; follow instructions for missed pills and use backup contraception.
Take one pill at the same time every day, even if you don't have sex.,If you miss a pill, follow the instructions in the package insert or ask your healthcare provider.,Use a backup method (like condoms) if you start late or miss pills.,This medication does not protect against HIV or other sexually transmitted infections.,Common side effects include nausea, breast tenderness, and breakthrough bleeding.,Seek medical help if you have symptoms of a blood clot: sudden chest pain, leg swelling, or shortness of breath.,Smoking while on this pill increases your risk of serious cardiovascular events.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CYCLAFEM 7/7/7 vs AFIRMELLE, answered by our medical review team.
CYCLAFEM 7/7/7 is a Oral Contraceptive that works by Combination estrogen-progestin contraceptive. Ethinyl estradiol suppresses gonadotropin release (FSH, LH) via negative feedback on hypothalamic-pituitary axis; norethindrone induces endometrial changes that inhibit implantation and thickens cervical mucus.. AFIRMELLE is a Combined Oral Contraceptive that works by Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CYCLAFEM 7/7/7 and AFIRMELLE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CYCLAFEM 7/7/7 is: One tablet (norethindrone 0.5 mg/ethinyl estradiol 35 mcg) orally once daily for 7 days, then one tablet (norethindrone 0.75 mg/ethinyl estradiol 35 mcg) orally once daily for 7 days, then one tablet (norethindrone 1 mg/ethinyl estradiol 35 mcg) orally once daily for 7 days. Dispensed in a 21-tablet pack with 7 placebo tablets. For contraception, take one tablet daily at same time each day for 28 days; begin next pack after 28-day cycle.. The standard adult dose of AFIRMELLE is: One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CYCLAFEM 7/7/7 and AFIRMELLE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CYCLAFEM 7/7/7 is classified as Category C. Pregnancy Category X. First trimester: Major birth defects including neural tube defects, cardiovascular malformations, and oral clefts. Second/third trimester: Fetal demasculiniza. AFIRMELLE is classified as Category C. Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.